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SUMMARY
Many xenobiotics can bind to off-target receptors and cause toxicity via the dysregulation of down-
stream transcription factors. Identification of subsequent off-target toxicity in these chemicals has
often required extensive chemical testing in animal models. An alternative, integrated in vitro/in silico
approach for predicting toxic off-target functional responses is presented to refine in vitro receptor
identification and reduce the burden on in vivo testing. As part of the methodology, mathematical
modeling is used to mechanistically describe processes that regulate transcriptional activity following
receptor-ligand binding informed by transcription factor signaling assays. Critical reactions in the
signaling cascade are identified to highlight potential perturbation points in the biochemical network
that can guide and optimize additional in vitro testing. A physiologically based pharmacokineticmodel
provides information on the timing and localization of different levels of receptor activation informing
whole-body toxic potential resulting from off-target binding.
INTRODUCTION
Many drugs are designed to interact specifically with cell surface, cytoplasmic, or nuclear receptors to pro-
duce a beneficial therapeutic effect. However, drugs can often bind to and interact with receptors that are
not their intended targets, and such ‘‘off-target’’ binding may cause what is now often termed a molecular
initiating event (MIE), e.g., receptor activation of toxicological relevance that may ultimately lead to an
adverse drug reaction (ADR) (Edwards and Aronson, 2000; Guengerich, 2011; Muller and Milton, 2012).
In many instances, ADRs can lead to significant morbidity and mortality as well as contribute to high levels
of attrition during drug development (Lazarou et al., 1998; Pirmohamed et al., 2004). This can primarily be
attributed to an incomplete understanding of themolecular mechanism of action of a given compound and
the lack of ability to predict which receptors may be activated unintentionally.
The sole use of in vitro-based experimental strategies in the early stages of drug development and chem-
ical testing is important but can lead to an unreliable and incomplete understanding of reactions (Coleman,
2011). Therefore, often considerable numbers of animals are used to screen out chemicals that may cause
off-target toxicity, with figures for the UK reporting that 306,000 in vivo toxicology safety procedures were
performed in 2014 (Home Office, 2015). In addition, the chemical industry used almost 345,000 animals in
the EU for toxicological or other safety evaluations (European Commission, 2013), and in the United States
3–6 million fish are used annually for whole effluent toxicity testing (Scholz et al., 2013). Furthermore, phar-
macokinetics and pharmacodynamics are significantly different between animal models and humans, di-
minishing their effectiveness in detecting toxicity through pre-clinical studies (Lauschke et al., 2016). There
is therefore a clear need to develop scientific approaches to identify toxicologically relevant off-target re-
ceptor binding to reduce the burden of animal use in toxicity testing. The development of a more ethical,
non-animal toolkit for initial chemical toxicological assessment using an integrated human-based in vitro/in
silico system would enhance current strategies and may even expedite the drug development pipeline.
In intracellular signaling, ligand/receptor interactions lead to the activation of a distinct set of transcription
factors, the effects of which tend to be tissue specific. Several companies now offer transcription factor acti-
vation profiling platforms, and so it is possible to identify and catalog the transcription factor activation
profiles of toxicologically relevant receptors upon binding of their known ligands/drugs. It is assumed
that transcription factor profiles generated from off-target receptor activation of any given drug can be
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matched against known ligand/receptor transcription profiles to predict which specific receptor (or class
of receptors) has been activated in the initial off-target MIE. However, when testing off-target profiles of
new compounds, the resulting transcription profile may not precisely match that of a known receptor
(e.g., partial agonism or the binding of multiple receptors), and therefore a method of refinement is
required to narrow the subset of off-target receptors. Our approach aims to refine the in vitro receptor
identification process for off-target receptors by using information about the changes in receptor-medi-
ated transcription factor activity following the introduction of a given compound and integrating this infor-
mation with predictive in silico models and analysis. This approach allows for the identification of relevant
perturbations in the transcription factor signaling pathway that signify the binding of a receptor or smaller
range of receptors as well as other points of interest in the transcription factor signaling network that can
contribute toward and guide subsequent off-target receptor identification.
Translating the wealth of knowledge on network interactions of cellular components to dynamic models is
generally limited by the amount of available quantitative information to accompany these relationships,
such as molecular amounts and reaction rates. However, qualitative dynamic network modeling can be
used to compare with routinely generated semi-quantitative experimental time course data, where pertur-
bations can provide valuable information about the system. In silico modeling of this type then provides a
platform for the refinement of more quantitative (parameter-based) modeling (Fisher et al., 2013). In such a
scenario, the network modeling method of Petri nets provides an effective tool, particularly in the complex,
stochastic framework of molecular biological pathways (Chaouiya, 2007; Heiner et al., 2008; Heidary et al.,
2015). Petri nets are often used tomodel multiple species and reactions without defining large quantities of
unknown parameters, as modeling emphasis is on network topology and relative amounts of species rather
than on specific reaction rates. This emphasis on network structure can then be translated to methods such
as flux balance analysis and metabolic control analysis (MCA) without knowledge of rate constants, as was
shown for the switching of the metabolic pathway in E. coli (Edwards et al., 2001; Kitano, 2002).
The identification of off-target receptor binding alone for a given compound is insufficient to predict
significant off-target toxicity, and so we aim to provide additional information to support and refine the
subsequent evaluation of toxic potential. This is achieved by translating knowledge of receptor binding
properties and relative distribution of the receptor throughout the body to a whole-body response to
the xenobiotic. This approach utilizes a physiologically based pharmacokinetic (PBPK) model adapted spe-
cifically for describing receptor activation throughout the body following compound exposure. A PBPK
model is a mechanistic, multi-compartment mathematical model that describes the time course dynamics
and overall kinetics of an administered drug dose throughout the organism of interest. PBPK models inte-
grate the physicochemical properties of the substance with the specific physiology of the organism such
that the evolution of the ADME (absorption, distribution, metabolism, and excretion) processes can be
simulated in silico. Drug/substance properties include tissue affinity, membrane permeability, enzymatic
stability, etc., whereas the organism/system components include properties such as organ mass/volume
and blood flow (Rowland et al., 2011). PBPK modeling is used in this work to couple the pharmacokinetics
of a drug to dose-response parameters with the associated off-target receptor in different tissues to
generate spatiotemporal dynamics of the off-target receptor activation.
RESULTS
Development of the Signaling Pathway Model
As proof of concept, an in silicomodel of the histamine H1 receptor signaling pathway was formulated. This
pathway was chosen owing to the well-understood intracellular signaling interactions involved upon recep-
tor stimulation and the existence of a known off-target partial agonist, lisuride (Bakker et al., 2004). The H1
receptor is a G-protein-coupled receptor that, upon activation, leads to dissociation of Gaq/11 and the
Gbg complex. Gaq/11 activates phospholipase Cb (PLCb), leading to hydrolysis of phosphatidylinositol
4,5-biphosphate (PIP2) and the formation of inositol triphosphate (IP3) and diacylglycerol (DAG) (Bakker
et al., 2001; Sandal et al., 2013). IP3 mediates a transient intracellular calcium release from the ER (Shah
et al., 2015) that eventually mediates the activation of nuclear factor of activated T-cells (NFAT) (Macian,
2005), cAMP response element-binding protein (CREB) (Johannessen and Moens, 2007), and myocyte
enhancer factor-2 (Mef2) transcription factors (Lu et al., 2000). DAG simultaneously activates protein
kinase C (PKC), and this phosphorylates IkB kinase (IKK), ultimately leading to nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) transcription factor activation (La Porta and Comolli,
1997). The Gbg complex also plays a role in histamine signal transduction, regulating many effectors,
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including adenylate cyclase (AC) (Maruko et al., 2005) and phosphoinositide 3 kinase (PI3K) (Gautam et al.,
1998). AC mediates the subsequent activation of protein kinase A via cyclic AMP (cAMP) leading to CREB
phosphorylation and transcription factor activation (Mosenden and Taske´n, 2011). PI3K mediates the acti-
vation of Akt, NF-kB, and activating transcription factor 2 (ATF2) (Bence et al., 1997; Breitwieser et al., 2007).
To provide semi-quantitative information for the relative transcription factor dynamics as described earlier,
we assayed pathway perturbations using a luciferase reporter-based transcription factor array to calibrate
the fold increase expected of key signaling outputs upon stimulation with an agonist. These transcription
factors were identified as NFAT, NF-kB, CREB,Mef2, and ATF2. Incubation of H1 receptor-expressing HeLa
cells with histamine showed considerable activation of these transcription factors (Table 1).
A stochastic Petri net model of the histamine H1 receptor signaling pathway was formulated based on
existing knowledge of the pathway and network interactions with the five critical transcription factors deter-
mined to be activated following ligand binding. The pathway in this proof of concept provides an illustra-
tive example of what should ultimately form part of a larger cell signaling model that incorporates the
complexity of the known toxicological receptors and associated transcription factors in the proposed
methodology. The H1 Petri net includes the key dynamic molecular species and appropriate network inter-
actions that are activated during ligand-binding-induced signaling. This pathway is depicted using the
modified Edinburgh pathway notation (mEPN) format (Freeman et al., 2010) in Figure 1 and directly corre-
sponds to the layout of the Petri net. All rates are equal such that all stochastic transitions are equally likely
to fire but are effectively modulated by the concentration of upstream reactants in a mass action process.
Time is interpreted qualitatively reflecting the relative order of events. Varying quantities in the mathemat-
ical model, such as the amount of ligand introduced (‘‘dose’’) and the total amounts of system species (i.e.,
moieties of active and inactive states for each protein), modulate the scale of transcriptional activity regu-
lation, and as such, these values were optimized to correlate with the experimental signaling assays. This
optimization was carried out by assuming a large-scale continuum approximation of the Petri net to a sys-
tem of ordinary differential equations (ODEs) and fitting to the corresponding transcription factor output
data (Figure 2). It should be noted that the optimal parameter set is non-identifiable for such a large system
with relatively few data points to fit. However, this issue was the precise motivation for the combined Petri
net/MCA approach, which is well suited to understanding the relative impact of small perturbations on
the transcription factors of interest and prioritize network connectivity information in favor of accurate
predictions of parameters and dynamics (Koch et al., 2010). Corresponding pathway reactions, moieties,
and ODEs can be found in the supplementary material. In addition to providing static information on
the network interactions of the signaling pathway and relative changes in steady state activity following
receptor activation, Petri nets can also be used to simulate transient temporal dynamics, providing further
dynamic information on the relative order and scale of transcriptional regulation (Figure 3) following a re-
ceptor-ligand binding event. However, it is clear that more data would be required for one to relate this
dynamic output to the biological context and validate any potential predictions about transient dynamics.
Analysis of Network Perturbations to Identify Off-Target Responses
The identification of significant pathway reactions upstream of transcription was achieved using metabolic
control analysis (MCA), which is a mathematical technique that tests the sensitivity of a given variable to
network perturbations (Kacser and Burns, 1973; Heinrich and Rapoport, 1974). Specifically, scaled MCA
Transcription Factor Fold Change in Relative
Luciferase Units
NFAT 1.97G 0.063
NF-kB 2.18G 1.47
CREB 1.54G 0.027
MEF2 2.74G 1.31
ATF2 1.67G 8.99
Table 1. Transcription Factor Changes
Alterations in expression levels of specified genes in the presence of histamine after 6 hr expressed as mean fold changes in
relative luciferase units with SD(n = 3) as determined by Cignal reporter assay.
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concentration control coefficients provide the ratio between a relative measure of change in the steady
state of a system variable as affected by perturbations in network reaction rates. In our illustrative H1
example model, MCA coefficients were calculated for each transcription factor that was experimentally
determined to show significant change in activity following binding of the H1 receptor (Figure 4). The
rows of the heatmap in Figure 4 correspond to the numbered reactions as indicated in the supplementary
material. MCA points not only to the direct regulation of gene transcription as critical to H1-associated
Figure 1. Schematic Representation for the Petri Net of the Histamine H1 Receptor Signaling Pathway Using mEPN Notation
The Petri net describes the key relationships between components of the signaling pathway system culminating in the regulation of downstream
transcription factor expression stimulated by the binding of a ligand to the histamine H1 receptor.
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transcriptional activity (white patches in Figure 4), but also to other reactions within the cascade, upstream
of the transcription factors and downstream of the target receptor. For example, in this system the tran-
scriptional activity of Mef2 is sensitive to relatively distant biochemical reactions, such as the rate of calcium
release from the ER (24% of maximum sensitivity provided by perturbation of Mef2 transcription rate). Also,
the model suggests that the transcriptional activity of ATF2 is more sensitive to perturbations in PIP2 syn-
thesis than to the regulation of the BTK:PIP3 complex that directly activates ATF2 by phosphorylation.
The identification of these sensitive perturbation points within the signaling pathway model provide infor-
mation beyond the transcription factor activity measurements found experimentally, which allows for more
optimized, directed experimental designs for receptor identification, if initial screening fails to identify the
off-target receptor. For example, for a given compound that was shown to regulate Mef2 transcriptional
activity but did not interact with the H1 receptor, this model would inform a proposal to screen for recep-
tors that are known to interact with biochemical reactions identified as being sensitive, such as calcium
release, during MCA.
Translation to Tissue Scales Using a PBPK Model
Following an in silico identification of an off-target receptor, extrapolation to the study of potential in vivo
toxicity can be performed using a PBPK model. For our illustrative example, receptor binding properties
are provided by EC50 dose-response curves for the off-target H1 agonist, lisuride (Figure 5A), andmeasure-
ments of the corresponding binding affinity, Kd (Bakker et al., 2004). The dose-response curves were esti-
mated by fitting the following equation to the dose-response data:
Response%=Min+
ðMax MinÞLn
ECn50 + L
n
; (Equation 1)
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Figure 2. Optimized Transcription Factor Output
The ligand (histamine) was introduced at t = 0 (Petri net time units) in the model simulation. Before t = 0 the model was run
to steady state. Themodel solution was fit to the data via optimization of the conservedmoieties of the signaling pathway.
Dotted lines represent the fold increase in transcriptional activity for the relevant transcription factor observed in the
transcription assays. Solid lines represent the normalized model solution for the corresponding transcriptional activity as
simulated by luciferase dynamics.
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for ligand concentration L. The optimized parameter values are given in Table 2. To provide tissue-
specific responses we also used western blot measurements of relative H1 receptor expression in
different tissues (Figures 5B and 5C) and calculated modified tissue-specific EC50 values using
EC50i =
KdEC50
RiðKd +EC50Þ  EC50
where i denotes the ith tissue, Kd is the dissociation equilibrium constant for lisuride, and Ri is a mea-
sure of receptor abundancy in tissue i (see Table 3). For simplicity, this model assumes that the same
amount of receptor binding is required to achieve 50% response in each tissue in the absence of any
other information, particularly as the responsemeasured is proximal to receptor binding attenuating
any potential amplification effects arising from potential signaling cascades in different tissues
(Kenakin, 2009). For further information regarding this derivation see the Supplemental Information.
To simulate the pharmacokinetics of lisuride throughout the body, physicochemical properties of the com-
pound were required, which were obtained from previously published measurements. These properties
include lipophilicity, whether the drug is neutral/acid/base, solubility (obtained from the DrugBank data-
base [Wishart et al., 2006]), molecular weight (O’Neil, 2013), acid dissociation constant (Meloun et al.,
2005), and effective permeability (Winiwarter et al., 1998). The time course dynamics simulated by the
PBPKmodel for drug concentration in each tissue compartment of the body were then coupled to receptor
binding properties and relative receptor expression in tissues to provide a predictive temporal response
throughout the body. This response can be produced for any dosage regimen and various methods of
administration, such as intravenous, oral, and inhalation. The PBPK model was based on the form derived
by Peters (2008). The model was optimized for lisuride physicochemical and binding properties and the
H1 receptor distribution throughout the different tissues. Example lisuride response kinetics following
both intravenous (IV) and oral administrations can be found in Figure 6. The IV dose of 25 mg/mL used in
Figure 6 was the same as that used in a previous pharmacokinetic study for relevance (Krause et al.,
1991). These experimental data were also the IV data used to optimize the PBPK model to recapitulate
the lisuride dynamics in the venous blood compartment and also simulate corresponding oral profiles as
per the methodology described by Peters (2008). The oral dose of 0.1 mg chosen for the PBPK model
was deemed relevant by matching previous pharmacological studies (Koizumi et al., 1985; Al-Sereiti and
Turner, 1989). The dynamic response of the H1 receptor is visualized over time as a solution to Equation (1)
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Figure 3. Transient Dynamic Output of the Histamine H1 Receptor Signaling Pathway Using the Stochastic
Petri Net
This figure illustrates the dynamic output of the stochastic Petri net when a small transient perturbation to the ligand
concentration is made at t = 200 units, representing the pre-stimulation steady state. Dynamics are shown for model
variables that correspond to luciferase signals for transcription factors associated with a receptor stimulation
perturbation.
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with tissue-specific EC50 values for the pharmacokinetics of lisuride (L) in different parts of the body. Both IV
and oral administration simulations are plotted to also highlight the impact of delivery route. This is partic-
ularly pertinent in this case where we are studying a receptor that has a relatively high concentration in the
gastrointestinal tract. IV administration results in relatively high receptor stimulation in the liver, brain, small
intestine, and colon at earlier times, whereas oral administration results in a more gradual accumulation in
these tissues and the receptors in the colon are stimulated at a near-maximal level for a relatively long time
after oral ingestion. These simulations allow us to compare how the off-target response varies throughout
the body over time depending on the pharmacokinetics of the drug coupled with physiologically relevant
receptor availability and receptor binding information. Such information is potentially useful to determine
whether or not an identified off-target agonist is likely to elicit an off-target receptor response in an area of
high target density based on its physicochemical properties.
DISCUSSION
ADRs are a major cause of patient morbidity, mortality, and drug attrition during development (Pirmo-
hamed et al., 2004). This can be attributed to a poor understanding of the mechanisms underlying the toxic
response and also to a lack of current tools for the prediction of a toxic outcome. Animal models have a
limited scope, and data obtained using such models may not be ideal for ascertaining toxicity seen in hu-
mans. As such, computational systems biology models can be essential tools to improve chemical reaction
predictivity (Krewski et al., 2010). In this study, we describe a new in silico modeling method that can be
used to enhance the current knowledge of pathway perturbations to provide a new toxicity-testing para-
digm based on human biology. In this method, chemical-mediated activation of transcription factors
and intracellular signaling pathway molecules were used as readouts to inform and drive a pathway-based
in silico approach to identify possible upstream receptor(s) engaged by such chemicals. In vitro data were
then used to inform a PBPK in silicomodeling platform to understand and rank the risk of toxicity at tissue,
organ, and whole-body levels over time. Key to this integrative approach was the coupling of in vitro
experimental techniques and advanced in silico modeling to create a unique resource that, with further
NFAT NF- B CREB MEF2 ATF2
Transcription Factors
10
20
30
40
50
60
70
80
Pa
th
w
ay
 re
ac
tio
ns
0
10
20
30
40
50
60
70
80
90
100
Se
ns
iti
vi
ty
 
(%
)
Figure 4. Metabolic Control Analysis (MCA) of the H1 Signaling Pathway
Scaled concentration control coefficients as a result of MCA are plotted for the activity of five transcription factors
modulated by histamine H1 receptor binding. Each row of the heatmap numerically corresponds to a reaction term in the
signaling pathway model (see Supplemental Information). Maximum and minimum values in the heatmap (white patches)
represent maximum sensitivity to perturbation of the reaction terms in the model depicting direct transcriptional
regulation rates and luciferase decay rates.
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development and parameterization, could be used to predict the off-target toxicity of compounds that can
then inform and direct more focused in vivo experimentation.
Mathematical modeling was used to mechanistically describe the processes that lead to regulation of tran-
scriptional activity following the binding of ligand to receptor. This was achieved by designing a signaling
pathway model that represented all the relevant processes and biochemical reactions downstream of
ligand binding, culminating in the regulation of transcription. We have established a novel in vitro/in silico
approach using data from assays measuring transcription factor activation and chemically induced pertur-
bations of intracellular signaling pathways to inform in silico pathway modeling. This unbiased pathway-led
approach uses computational simulations to identify causality between receptor activation and pathway
perturbations to aid identification of the upstream receptor/s engaged by the initial MIE. As proof of
concept, an in silico Petri net model of the histamine H1 receptor-signaling pathway was formulated
Figure 5. Histamine/Lisuride Dose Response, EC50, and Kinetic Parameters
(A) Ligand (histamine) and partial agonist (lisuride) dose-response assays used to calculate EC50 values.
(B) Immunoblotting of H1 receptor in murine organs.
(C) Relative quantification of immunoblot relative to HeLa cell lysates.
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with the off-target compound, lisuride. The output of this system provides semi-quantitative temporal dy-
namics for the entire pathway that can be used to investigate system perturbations, simulate experiments,
and provide structural pathway predictions. In vitro reporter assay data were then used to parameterize
and validate the model, and the identification of critical candidate perturbation points was achieved using
MCA. Signaling pathway models can be purposely used in this methodology to provide a library of MCA
coefficients for a range of transcription factors associated with receptor binding and toxicity and guide
further experimentation. In the example shown, calcium release from the ER and PIP2 synthesis are high-
lighted as important upstream events for the transcriptional activity of Mef2 and ATF2. If a new compound
is shown to induce the activity of these transcription factors but the receptor responsible is not identified via
screening, for instance, further testing could be guided toward targets that modulate these upstream pro-
cesses. This illustrates the feasibility of this approach in directing further experimentation toward relevant
pathway mechanisms or receptor clusters during the process of receptor identification via focused in vitro
assay testing.
In vitro to in vivo extrapolations of whole-body consequences of receptor binding was explored using
PBPK modeling. The structure of PBPK models typically revolves around the anatomical structure of the
organism, with different organs and tissues of varying perfusion rates being separated into distinct com-
partments. These compartments are then coupled through the circulation, whose arterial and venous
flow is described to connect the organs in a physiological way. Entrance points (e.g., absorption) of the
model depend on the drug administration method (e.g., inhalation, ingestion, injection), whereas exit
points (e.g., excretion) are generally described via the kidneys and intestine. The flow kinetics of the model
determine distribution, whereas metabolism occurs in the liver and intestine. The inherent physiological
basis distinguishes true PBPK models from their PK model counterparts that usually simplify the physiology
to fewer hypothetical compartments of different flow rates, driven by the data/process of interest, such that
they are often more tractable analytically. In contrast, PBPK models are generally more complex but are
designed to have a better global representation such that valid extrapolations can be made and disparate
experimental data can be integrated during model parameterization. In this way, PBPK models are less
reliant on data fitting to obtain appropriate values for equation parameters and essentially the samemodel
(with appropriate modifications) can be suitably applied in many different pharmacological scenarios for
quantitative risk assessment and therapy optimization.
PBPK model simulations are increasingly being used in pharmacology, in both academia and industry, to
provide important predictions of the pharmacokinetic properties and toxic potential of new drugs at an
early stage in drug development (Zhao et al., 2011; Jones and Rowland-Yeo, 2013; Tsamandouras et al.,
2015). This type of in silico testing can offer a quicker, cheaper, and more ethical alternative method
when compared with traditional in vivo experiments performed. Ideally, both experimental and computa-
tional methods are used harmoniously to provide a cycle of information and enhanced knowledge iteration
as the accuracy of PBPK models inevitably rely on quality experimental data to calibrate rates within the
differential equations. In the method reported here, physicochemical properties of the chemical are
combined with tissue-specific receptor expression and EC50 data to predict time course dynamics of the
chemical concentrations in each tissue, as well as tissue-level receptor-activation responses to that
chemical. These predictions can be produced for any dosage regimen and various methods of administra-
tion. In the example study of the off-target partial agonist of the histamine H1 receptor, lisuride, the com-
bination of lisuride pharmacokinetics and relative H1 receptor distribution throughout the body allowed us
Parameter Value SE Units
Min 7.98% 1.066 /
Max 36.55% 0.5863 /
logEC50 7.968 0.06724 mol/L
n (Hill coefficient) 0.8411 0.1009 /
Kd 8 3 10
9 0.0577 mol/L
Table 2. Kinetic Parameters of Lisuride and the Histamine H1 Receptor
Receptor activation of the H1 histamine receptor was studied with known agonist (histamine) and off-target agonist (lisuride).
Using these assays, each parameter was calculated using GraphPad Prism.
92 iScience 4, 84–96, June 29, 2018
to predict that the dose response would be most significant in the brain, liver, and gastrointestinal system.
In this case example, these results are supported by prior knowledge of the compound and receptor,
although the modeling was done agnostic of such prior in vivo findings. In particular, receptor response
localized to the brain is somewhat expected since lisuride is primarily a psychotherapeutic drug, affecting
dopamine and serotonin regulation (Marona-Lewicka et al., 2002). Lisuride is primarily metabolized in the
liver, where there is a relatively high expression of histamine receptors. There is also high receptor expres-
sion in the gastrointestinal tract owing to the role of histamine in intestinal secretion and motility (Leurs
et al., 1995; Sander et al., 2006). Furthermore, lisuride administration in patients with Parkinson disease
has been associated with gastrointestinal side effects (Ebadi and Pfeiffer, 2004). Although relative response
rates have been quantified by the model in different parts of the body at different times, to translate what
such a response directly represents in the context of toxicity and clinical relevance is very complicated, and
restricted in this methodology, establishing a challenge beyond the scope of this paper. However, these
PBPK-based extrapolations do allow us to generate predictive data relevant to risk assessment and further
translation to toxicity at the organ and whole-body levels for off-target receptor perturbations. The output
provided by this method is intended to identify toxic potential and guide subsequent in vitro and in vivo
experimentation to organs of interest/importance.
The operating parameters of the approach are circumscribed by the extent of current knowledge regarding
receptors and their function. This represents a potential limitation of the strategy, although the mathemat-
ically driven signaling pathway model has the potential to identify novel, uncharacterized receptor targets.
The challenge of identifying sensitive perturbation points within large-scale networks of receptor signaling
pathways required that a semi-quantitative network-based approach be used. This inevitably limits the
amount of predictive, dynamic information that can be extrapolated, and caution must be exercised
such that the utility of mathematical models is preserved by acknowledging the relevant application that
stimulated its design. The approach is experimental (with elements of modeling and extrapolation to
assess and rank toxicological risk) and does not incorporate prediction of receptor binding based on chem-
ical or receptor structures. The strength of the methodology is predicated on currently available, validated
experimental methods, as it does not require the development of new, untested technologies and relies on
sound criteria-based selection of receptors and quantifying receptor function and binding using estab-
lished experimental techniques. Future work requires the development of multiple pathway models based
on training chemical data as well as the integration of pathways, which should be optimized and validated
with non-training data. Furthermore, the current PBPK framework can be extended to ensure improved
predictive potential by incorporating mechanistic tissue models, catering for a wider range of chemicals
and capturing population-level responses. More work is also needed to translate tissue-level receptor acti-
vation responses to measures of toxicity, such as relevant biomarkers. Carefully calculated person-to-per-
son variation and covariances within organism-related parameters would also allow for the prediction of a
population response whereby different individuals within a sample population may exhibit different levels
of exposure and therefore associated toxicity from the same dosage levels. The combined in vitro/in silico
Parameter Value Tissue
RHE 5.60 Heart
RLU 3.56 Lungs
RKI 6.64 Kidney
RLI 11.63 Liver
RBO 3.88 Skeletal muscle
RBR 5.78 Brain
RSP 5.83 Spleen
RSI 5.56 Small intestine
RCO 25.90 Large intestine
Table 3. Relative Amounts of Histamine H1 Receptor in Murine Tissue Calculated Using Immunoblot Analysis
Values were used to calculate tissue-specific receptor scaling factors for lisuride EC50 values when binding to the histamine H1
receptor.
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approach of this study has shown how the multidisciplinary, iterative process of systems biology can be
applied to direct experiments, optimize the utility of generated data, and challenge and refine theoretical
modeling to improve methods for detecting and predicting toxicity caused by compounds that bind to off-
target receptors.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, two figures, and four tables and can be found
with this article online at https://doi.org/10.1016/j.isci.2018.05.012.
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Experimental Methods 
Cell culture 
HeLa cells were cultured in DulbeccoÕs Modified Eagle Medium supplemented with 10% 
foetal bovine serum, 2 mM glutamine and incubated at 37 ¡C in a 5% CO2 humidified 
atmosphere. 
Quantification of transcription factor activation 
Transcription factor activation was measured using Cignal Reporter dual-luciferase assay 
(Qiagen) as per manufacturerÕs instructions, to determine intracellular signal transduction 
perturbation and transcription factor activation data for in silico modelling. Briefly, HeLa 
cells were plated in 96-well plates and transfected with inducible transcription factor 
responsive constructs composed of specific transcription factor response elements linked to 
firefly luciferase along with a constitutively expressing Renilla construct as an internal 
control. Transfection was performed with Attractene transfection reagent (Qiagen) as per 
manufacturerÕs instructions. Transfected cells were stimulated with histamine (Sigma) for 6 
or 24 h and activation of specific transcription factors quantified by luminometer using the 
Dual-Luciferase Reporter Assay System (Promega). 
Receptor activation 
Activation of histamine receptor H1 with its known agonist, histamine and the off-target 
partial agonist, lisuride was determined using PathHunter¨ Chinese Hamster Overy (CHO)-
K1 reporter cells that over-express ProLinkª-tagged human histamine H1 receptor and the 
Enzyme Acceptor (EA)-tagged β-Arrestin (DiscoverX) as per manufacturerÕs instructions. In 
these cells activation of histamine receptor H1 by a ligand forces H1 receptor coupling with 
EA-tagged β-Arrestin leading to the formation of a functional enzyme that is able to generate 
a chemiluminescent signal upon substrate cleavage. These assays were used to calculate 
EC50 values for both histamine and lisuride.  
Immunoblotting analysis  
Mouse organs from wild type C57 mice (Charles River) were snap frozen in liquid nitrogen 
and whole tissue lysates homogenised in lysis buffer (250 mM sucrose, 50 mM Tris.HCl,1 
mM MgCl2, 1% Triton X-100, 1 mM PMSF). Lysates were also generated from HeLa and 
CHO cells over-expressing histamine H1 receptor. The lysates were centrifuged at 5000 g for 
15 minutes at 4 ¡C and 20 µg of total protein separated using SDS-PAGE and analysed using 
standard immunoblotting techniques. Membranes were blocked overnight in 5% milk powder 
in blocking buffer (0.2% Triton X-100 in PBS) at 4 ¡C and then incubated with rabbit 
polyclonal anti-H1R antiserum (Abcam; 1:1000) followed by horseradish peroxidase-
conjugated goat anti-rabbit antiserum (Jackson Labs; 1:2500). Immuno-reactive proteins were 
visualized using enhanced chemiluminescent substrate detection (ThermoFisher). 
Densitometry analysis was carried out using Image J and fold-changes in expression relative 
to HeLa cells calculated. 
Petri Nets 
The stochastic Petri net model of the histamine H1 receptor signalling pathway was 
formulated using Snoopy software (Heiner et al., 2012). In the context of cellular signalling 
pathways, a Petri net is a bipartite graphical representation of a biochemical network with 
ÒtokensÓ/dots-or-numbers (representing number of molecules or concentration) in 
ÒplacesÓ/circles (network species, proteins etc.). A reaction is represented by the ÒfiringÓ of a 
ÒtransitionÓ/square where tokens are moved from one place to a downstream place as 
indicated by connecting ÒarcsÓ/arrows. A transition may fire only if all upstream places 
contain sufficient tokens, i.e. all reactants must be present for a specific reaction to occur. 
Petri nets use mass action and Gillespie algorithm principles such that transitions with a 
higher number of upstream tokens fire with a higher probability.  
Parameter Optimisation and Metabolic Control Analysis 
The signalling pathway model large-scale continuum approximation to an ODE system was 
solved using a Runge-Kutta 4/5
th
 order method with Matlab R2015b software. Pathway 
moieties (conserved quantities defined in supplementary material S1.2) were optimised such 
that model signalling output was consistent with experimental data. Optimisation was carried 
out by minimising the error between fold-increase in transcription factor levels in the model 
and the data. Metabolic scaled concentration control coefficients were calculated using 
Copasi 4.15 software (Hoops et al., 2006). The Peters (2008) PBPK model code was written 
and solved with Matlab R2015b software. 
1! Modelling the H1 receptor signalling pathway 
Table S1, related to Figure 1: Histamine H1 receptor signalling pathway reactions. Each reaction in the Petri net of Figure 1 is described 
explicitly with associated description and mass action kinetics. 
Reaction 
No. 
Reaction Description Mass action flux terms 
1.!  ! + #: %&: '()*+ → !:# + %& + '()-+ Ligand binding causes dissociation of '()-+ 
(i.e. GTP bound	'() and %& from the receptor 
/0 = ! ∗ #: %&: '()*+ 
2.!  3#42 + %& → 3#42∗ Activation of G protein coupled receptor 
kinase 2 (3#42) by binding to free %&  
/6 = 3#42 ∗ %& 
3.!  3#42 + %&
789:78:;8<=>?@ABC
3#42∗ DEF: DE (defined below) mediated plus 
background deactivation of 3#42 
/G = 3#42
∗ ∗ DEF: DE + 3#42∗ 
4.!  '()-+ → '()*+ Background hydrolysis of '()-+to '()*+ /H = '()-+ 
5.!  '()*+ + 3#42
∗ → 3#42 + %&: '()*+		 '()*+ will scavenge %& from complexes to 
give a %&: '()*+	complex 
/I = '()*+ ∗ 3#42
∗ 
6.!  
!: #
)JK6∗
L!: # 
3#42∗  phosphorylates agonist-activated 
receptors 
/M = !: # ∗ 3#42
∗ 
7.!  L!: # → # The phosphorylated receptors are recognized 
by arrestins that bind to the receptor which 
targets it for internalization 
/N = L!: # 
8.!  !: # → #  Background degradation of ligand /O = !: #  
Reaction 
No. 
Reaction Description Mass action flux terms 
9.!  %& + '()*+ → %&: '()*+ '()*+ binding with free %& /P = %& ∗ '()*+ 
10.! %&: '()*+ + # → #: %&: '()*+ Binding of %&: '()*+ to free receptor to give 
#: %&: '()*+ 
/0Q = %&: '()*+ ∗ # 
11.! '()-+ + R!D → R!D: '()-+ R!D and '()-+ binding 
 
/00 = '()-+ ∗ R!D 
12.! R!D: '()-+ → R!D + '()*+ Dissociation of R!D: '()-+ hydrolyses '()-+ 
to '()*+ 
/06 = R!D: '()-+ 
13.! ∅ → RTR2 Background production/synthesis  /0G = U0 
14.! RTR2 → ∅ Background decay/utilisation /0H = RTR2 
15.! RTR2
+V7:WXYZ[
TR3 + ]^3 R!D: '()-+ catalysed separation of RTR2 
into	TR3 and ]^3 
/0I = RTR2 ∗ R!D: '()-+ 
16.! TR3 → ∅ Background decay/utilisation /0M = TR3 
17.! ]^3 → ∅ Background decay/utilisation /0N = ]^3 
18.! TR3 + _# → TR3: _# TR3 binding to receptors on the _# 
(endoplasmic reticulum) 
/0O = TR3 ∗ _# 
19.! TR3 + _# ← TR3: _# TR3: _# dissociation /0P = TR3: _# 
20.! ∅
a+G:bJ:;8<=>?@ABC
DE TR3: _# induces Calcium (DE) release from 
the _#. Plus background  release/production 
/6Q = TR3: _# + U6 
21.! DE → ∅ DE is sequestered back in to _#  /60 = DE 
Reaction 
No. 
Reaction Description Mass action flux terms 
22.!    
23.! DE + DEF → DEF: DE DE binds with Calmodulin (DEF).  /66 = DE ∗ DEF 
24.! DE + DEF ← DEF: DE DEF: DE dissociation /6G = DEF: DE 
25.! DEF: DE + DEc → DEF: DE: DEc DEF: DE binds to Calcineurin (DEc).  /6H = DEF: DE ∗ DEc 
26.! DEF + DEc ← DEF: DE: DEc DEF: DE: DEc dissociation /6I = DEF: DE: DEc 
27.! Lcd^e
789:78:78f
cd^e DEF: DE: DEc induced dephosphorylation of 
Lcd^e 
/6M = Lcd^e ∗ DEF: DE: DEc 
28.! Lcd^e → cd^e (background) dephosphorylation of Lcd^e	 /6N = Lcd^e 
29.! 
cd^e
)gKGh
Lcd^e 
Lcd^e = inactive cd^e (no signal) /6O = 3i43% ∗ cd^e	 
30.! cd^e → 	Lcd^e (background) phosphorylation of cd^e	 /6P = cd^e 
31.! 3i43%
+K7:*j)
L3i43% R4D:]^3 catalysed phosphorylation of 
glycogen synthase kinase 3 beta (3i43%) 
/GQ = 3i43% ∗ R4D:]^3 
32.! 
3i43%
j=l∗
L3i43% 
^Um∗ catalysed  phosphorylation of 3i43% /G0 = 3i43% ∗ ^Um
∗ 
33.! 3i43% ← L3i43% Dephosphorylation /G6 = L3i43% 
34.! ∅
fnj-
opq(F7 − 8)  Luciferase F7-8 signal /GG = cd^e 
35.! opq(d7 − 8) → ∅  Decay of luciferase signal /GH = opq(d7 − 8)  
36.! R4D + ]^3 → R4D:]^3 Binding /GI = R4D ∗ ]^3 
37.! R4D + ]^3 ← R4D:]^3 Dissociation   /GM = R4D:]^3 
Reaction 
No. 
Reaction Description Mass action flux terms 
38.!    
39.! T44
+K7:*j)
T44L R4D:]^3 catalysed  phosphorylation of T44 /GN = T44 ∗ R4D:]^3 
40.! 
T44
j=l∗
T44L 
^Um∗ catalysed  phosphorylation of T44 /GO = T44 ∗ ^Um
∗ 
41.! T44 ← T44L Dephosphorylation /GP = T44L 
42.! Twx
aKKy:;8<=>?@ABC
LTwx T44L catalysed phosphorylation of Twx.  /HQ = Twx ∗ T44L + Twx 
43.! Twx ← LTwx Dephosphorylation /H0 = LTwx 
44.! cdwx + Twx → Twx:cdwx Binding /H6 = cdwx ∗ Twx 
45.! Twx:cdwx
aKKy:;8<=>?@ABC
LTwx:cdwx T44L catalysed  phosphorylation of	Twx /HG = Twx:cdwx ∗ T44L
+ Twx:cdwx 
46.! LTwx:cdwx → LTwx + cdwx Dissociation  /HH = LTwx:cdwx 
47.! ∅
fnKz
opq(E11 − 12)  Luciferase E11-12 signal /HI = cdwx 
48.! opq(_11 − 12) → ∅  Decay of luciferase signal /HM = opq(_11 − 12)  
49.! %& + ^D → %&: ^D Binding of Adenylyl Cyclase (^D, an enzyme) 
to %& 
/HN = %& ∗ ^D 
50.! %& + ^D ← %&: ^D Dissociation  /HO = %&: ^D 
51.! '()*+ + %&: ^D → ^D + %&: '()*+		 '()*+ will scavenge %& from complexes to 
give a %&: '()*+		complex 
/HP = '()*+ ∗ 	%&: ^D 
52.! 
R4^
h}:j7
R4^∗ 
Activation of Protein Kinase A (R4^) /IQ = R4^ ∗ %&: ^D 
Reaction 
No. 
Reaction Description Mass action flux terms 
53.!    
54.! R4^ ← R4^∗ Dissociation  /I0 = R4^
∗ 
55.! 
D#_x
+Kj∗
LD#_x 
R4^∗ catalysed  phosphorylation of D#_x  /I6 = D#_x ∗ R4^
∗ 
56.! D#_x
789:78:789K
LD#_x DEF: DE: DEF4 (defined below) catalysed  
phosphorylation of D#_x 
/IG = D#_x ∗ DEF: DE: DEF4 
57.! D#_x ← LD#_x Dephosphorylation /IH = LD#_x 
58.! LD#_x + LD#_x → LD#_x: LD#_x Homerdimer formation /II = LD#_x ∗ LD#_x 
59.! D#_x + D#_x ← LD#_x: LD#_x Dissociation /IM = LD#_x: LD#_x 
60.! ∅
y7Jbz:y7Jbz
opq(A11 − 12)  Luciferase A11-12 signal /IN = LD#_x: LD#_x 
61.! opq(^11 − 12) → ∅  Decay of luciferase signal /IO = opq(^11 − 12)  
62.! DEF: DE + DEF4 → DEF: DE: DEF4 DEF: DE binding reversibly to DEF kinases 
(DEF4).  
/IP = DEF: DE ∗ DEF4 
63.! DEF + DEF4 ← DEF: DE: DEF4 Dissociation /MQ = DEF: DE: DEF4 
64.! FÄ2:Å]^D
789:78:789K:;8<=>?@ABC
FÄ2: LÅ]^D 
DEF: DE: DEF4 catalysed + background 
phosphorylation of Å]^D within the 
FÄ2:Å]^D complex.  
/M0 = FÄ2:Å]^D
∗ DEF: DE: DEF4
+FÄ2:Å]^D 
65.! FÄ2: LÅ]^D → FÄ2 + LÅ]^D Dissociation /M6 = FÄ2: LÅ]^D 
Reaction 
No. 
Reaction Description Mass action flux terms 
66.!    
67.! Å]^D
789:78:789K:;8<=>?@ABC
LÅ]^D DEF: DE: DEF4 catalysed + background 
phosphorylation of free Å]^D 
/MG = Å]^D ∗ DEF: DE: DEF4
+ Å]^D 
68.! LÅ]^D → Å]^D Background dephosphorylation /MH = LÅ]^D 
69.! FÄ2 +Å]^D →FÄ2:Å]^D Binding of myocyte enhancer factor-2 (FÄ2) 
to Å]^D.  
/MI = Å]^D ∗ FÄ2 
70.! 
∅
9ÇÉ6
opq(E3 − 4)  
Luciferase E3-4 signal /MM = FÄ2 
71.! opq(_3 − 4) → ∅  Decay of luciferase signal /MN = opq(_3 − 4)  
72.! %& + RT34 → RT34∗ Binding to give active phosphoinositol-3-
kinase (RT34∗).  
/MO = %& ∗ RT34 
73.! %& + RT34 ← RT34∗ Dissociation /MP = RT34
∗ 
74.! '()*+ + RT34
∗ → RT34 + %&: '()*+		 '()*+ will scavenge %& from complexes to 
give a %&: '()*+		complex. 
/NQ = '()*+ ∗ RT34
∗ 
75.! 
RTR2
+aGK∗
RTR3 
RT34∗  catalysed production of inositol lipid 
RTR3 from RTR2 
/N0 = RTR2 ∗ RT34
∗ 
76.! RTR3 → RTR2 Catalysed by PTEN (assumed constant) /N6 = RTR3 
77.! RTR3 → ∅  Background decay/utilisation /NG = RTR3  
78.! RTR3 + ^Um + R]4 → ^Um∗ Activation of ^Um.  /NH = RTR3 ∗ ^Um ∗ R]4 
79.! RTR3 + ^Um + R]4 ← ^Um∗ Dissociation /NI = ^Um
∗ 
Reaction 
No. 
Reaction Description Mass action flux terms 
80.!    
81.! xe4 + RTR3 → xe4: RTR3 Reversible binding of RTR3 with BrutonÕs 
tyrosine kinase (xe4).  
/NM = xe4 ∗ RTR3 
82.! xe4 + RTR3 ← xe4: RTR3 Dissociation  /NN = xe4: RTR3 
83.! ^ed2
z-K:+a+G:;8<=>?@ABC
L^ed2 xe4: RTR3 catalysed phosphorylation of 
activating transcription factor 2 (^ed2).  
/NO = ^ed2 ∗ xe4: RTR3 + ^ed2 
84.! ^ed2 ← L^ed2 Dephosphorylation /NP = L^ed2 
85.! ∅
yj-n6
opq(A1 − 2)  Luciferase A1-2 signal /OQ = L^ed2 
86.! opq(^1 − 2) → ∅  Decay of luciferase signal /O0 = opq(^1 − 2)  
87.! ∅ ↔ !  Basal degradation of ligand (and basal 
synthesis during infusion simulations)  
/O6 = UG − !  
  
 
 
 
 
 
 
 
Table S2, related to Figure 1: List of pathway moieties. Each equation represents a fixed total amount based on a sum of related variables. 
1 %&l@l8Ü = %& + #: %&: '()*+ + %&: '()*+ + %&: ^D + RT34
∗ +
3#42∗  
14 cdwxl@l8Ü = cdwx + Twx:cdwx + LTwx:cdwx  
2 #l@l8Ü = # + !: # + L!: # + #: %&: '()*+  15 ^Dl@l8Ü = ^D + %&: ^D  
3 '(l@l8Ü = '()-+ + '()*+ + R!D: '()-+ + #: %&: '()*+ +
%&: '()*+ = %&l@l8Ü  
16 R4^l@l8Ü = R4^ + R4^
∗  
4 3#42l@l8Ü = 3#42 + 3#42
∗  17 D#_xl@l8Ü = D#_x + LD#_x + 2LD#_x: LD#_x  
5 R!Dl@l8Ü = R!D + R!D: '()-+ 18 DEF4l@l8Ü = DEF4 + DEF: DE: DEF4  
6 _#l@l8Ü = _#	 + 	TR3: _#  19 Å]^Dl@l8Ü = Å]^D + LÅ]^D +FÄ2:Å]^D +FÄ2: LÅ]^D  
7 DEFl@l8Ü = DEF + DEF: DE + DEF: DE: Dc +
DEF: DE: DEF4  
20 FÄ2l@l8Ü = FÄ2 +FÄ2:Å]^D +FÄ2: LÅ]^D  
8 Dcl@l8Ü = Dc + DEF: DE: Dc  21 RT34l@l8Ü = RT34 + RT34
∗  
9 cd^el@l8Ü = cd^e + Lcd^e  22 ^Uml@l8Ü = ^Um + ^Um
∗  
10 3i43%l@l8Ü = 3i43% + L3i43%  23 R]4l@l8Ü = R]4 + ^Um
∗  
11 R4Dl@l8Ü = R4D + R4D:]^3  24 xe4l@l8Ü = xe4 + xe4: RTR3  
12 T44l@l8Ü = T44 + T44L  25 ^ed2l@l8Ü = ^ed2 + L^ed2  
13 Twxl@l8Ü = Twx + LTwx + Twx:cdwx + LTwx:cdwx    
 
 
 
Table S3, related to Figure 2: Pathway model ODEs (large-scale continuum approximation). The systems of ODEs representing the 
histamine H1 receptor signaling pathway are provided below. á[â]/ám represents the rate of change of variable â over time, m. Note that reaction 
/(å) corresponds to reaction å in Table S1.  
Ordinary Differential Equations 
á[!]
ám
	= 	/(82) 	− 	/(1) 
á[%&]
ám
	= 	/(1) 	+ 	/(3) 	+ 	/(48) 	+ 	/(69) 	− 	/(2) 	− 	/(9) 	− 	/(47) 	− 	/(68) 
á !: #
ám
	= 	/(1) 	− 	/(6) 	− 	/(8) 
á %&: '()*+
ám
	= 	/(5) 	+ 	/(9) 	+ 	/(49) 	+ 	/(70) 	− 	/(10) 
á 3#42∗
ám
	= 	/(2) 	− 	/(3) 	− 	/(5) 
á '()*+
ám
	= 	/(4) 	+ 	/(12) 	− 	/(5) 	− 	/(9) 	− 	/(49) 	− 	/(70) 
á L!: #
ám
	= 	/(6) 	− 	/(7) 
á '()-+
ám
	= 	/(1) 	− 	/(4) 	− 	/(11) 
á RTR2
ám
	= 	/(13) 	+ 	/(72) 	− 	/(14) 	− 	/(15) 	− 	/(71) 
á TR3
ám
	= 	/(15) 	+ 	/(19) 	− 	/(16) 	− 	/(18) 
á ]^3
ám
	= 	/(15) 	+ 	/(36) 	− 	/(17) 	− 	/(35) 
á TR3: _#
ám
	= 	/(18) 	− 	/(19) 
á DE
ám
	= 	/(20) 	+ 	/(23) 	− 	/(21) 	− 	/(22) 
á DEF: DE
ám
	= 	/(22) 	− 	/(23) 	− 	/(24) 	− 	/(59) 
á DEF: DE: DEF4
ám
	= 	/(59) 	− 	/(60) 
Ordinary Differential Equations 
á DEF: DE: Dc
ám
	= 	/(24) 	− 	/(25) 
á Lcd^e
ám
	= 	/(28) 	+ 	/(29) 	− 	/(26) 	− 	/(27) 
á L3i43%
ám
	= 	/(30) 	+ 	/(31) 	− 	/(32) 
á opq(d7_8)
ám
	= 	/(33) 	− 	/(34) 
á R4D: ]^3
ám
	= 	/(35) 	− 	/(36) 
á T44L
ám
	= 	/(37) 	+ 	/(38) 	− 	/(39) 
á Twx: cdwx
ám
	= 	/(42) 	− 	/(43) 
á LTwx: cdwx
ám
	= 	/(43) 	− 	/(44) 
á LTwx
ám
	= 	/(40) 	+ 	/(44) 	− 	/(41) 
á opq _11_12
ám
	= 	/(45) 	− 	/(46) 
á %&: ^D
ám
	= 	/(47) 	− 	/(48) 	− 	/(49) 
á R4^∗
ám
	= 	/(50) 	− 	/(51) 
á LD#_x
ám
	= 	/(52) 	+ 	/(53) 	− 	/(54) 	− 	2 ∗ /(55) 
á LD#_x: LD#_x
ám
	= 	/(55) 	− 	/(56) 
á opq ^11_12
ám
	= 	/(57) 	− 	/(58) 
á LÅ]^D
ám
	= 	/(62) 	+ 	/(63) 	− 	/(64) 
á FÄ2: Å]^D
ám
	= 	/(65) 	− 	/(61) 
á FÄ2L: Å]^D
ám
	= 	/(61) 	− 	/(62) 
Ordinary Differential Equations 
á opq _3_4
ám
	= 	/(66) 	− 	/(67) 
á RT34∗
ám
	= 	/(68) 	− 	/(69) 	− 	/(70) 
á RTR3
ám
	= 	/(71) 	+ 	/(75) 	+ 	/(77) 	− 	/(72) 	− 	/(73) 	− 	/(74) 	− 	/(76) 
á ^Um∗
ám
	= 	/(74) 	− 	/(75) 
á xe4: RTR3
ám
	= 	/(76) 	− 	/(77) 
á L^ed2
ám
	= 	/(78) 	− 	/(79) 
á opq ^1_2
ám
	= 	/(80) 	− 	/(81) 
 
 
 
 
2! Tissue-specific dose-response relationship derivation 
Lisuride response in CHO cells can be described as a function of lisuride concentration (! 
[mol/L]) as shown in equation (S1) for the parameters given in Table S4 based on data 
obtained by DiscoverX dose response assay (Figure S1).  
 
"#$%&'$#% = *+' +	
*./ −*+' !1
2345
1 	+ 	!1
 (S1) 
 
Table S4, related to Figure 6: Agonist response parameters. Parameter values used to 
describe the dose-response curve in Figure S1. 
Parameter Description Value Units 
*+'  Minimum response 7.98 % / 
*./  Maximum response 36.55 % / 
2345  Effective concentration 1.076 ! 10
-8 
mol/L 
'  Hill coefficient 0.8411 / 
 
 
 
 
 Figure S1, related to Figure 6: Ligand and agonist dose response assay. 
Dose response assays (DiscoverX) were used to calculate relevant EC50 values 
for both ligand (histamine) and agonist (lisuride). 
 
2.1! Defining the EC50 values for different cells and tissues 
We can describe the number of bound receptors using the equilibrium Langmuir-Hill 
equation: 
"67819 = ":7:;<
!
=> + !
 
where ":7:;< represents the total number of receptors (bound + unbound), ! represents ligand 
concentration and => is the dissociation equilibrium value.  
In CHO cells, let ":7:;< = ":7:;<
?@A . For the ligand concentration that causes 50% maximal 
response (i.e. ! = 2345
?@A) we can derive the corresponding amount of bound receptors, 
"67819
?@A
45
, namely: 
"67819
?@A
45
= ":7:;<
?@A
2345
?@A
=> + 2345
?@A
	. 
We would expect the 2345 value to vary between tissues, being dependent on the relative 
amount of receptors in that tissue. But for simplicity we will assume that the amount of 
bound receptors required for a half-maximal response is the same, i.e. "67819
?@A
45
=
"67819CD
E (for tissue +). Therefore, for tissue + we have a total number of receptors, ":7:;<
E , and 
a new 2345 value, 2345
E  defined as below: 
"67819
E
45
= ":7:;<
E
2345
E
=> + 2345
E
= ":7:;<
?@A
2345
?@A
=> + 2345
?@A
	, 
⇒ 2345
E =
=>2345
?@A
"
:7:;<
E/?@A
=> + 2345
?@A − 2345
?@A	
	, 
where ":7:;<
E/?@A
= ":7:;<
E /":7:;<
?@A . 2345
?@A is equal to the 2345 found in Table S4 and using the 
measured => for lisuride, we can modify our EC50 value for each tissue and update our dose 
response function in equation (S1) by measuring the relative amount of receptors in tissue + 
compared to CHO cells, ":7:;<
E/?@A
.  
 
  
3! Identifiability Analysis 
Pathway moieties were optimised to fit the steady state fold-changes of the transcription 
factors (Figure 2 of the main manuscript). Due to the nature of the approach taken 
(maximising network/pathway connectivity information rather than focusing on dynamics 
with a minimal model), there is an inevitable issue with model parameterisation. We have 
made efforts to find the global optimum for the parameter set through Latin hypercube 
sampling, but it is clear that other parameterisations could give fits that would at least look as 
good (by eye) and fit well within any expected variation from the biology/experimental error.  
A profile likelihood estimation method was employed to determine parameter identifiability 
analysis and, as expected, the results indicate that the parameters are not uniquely identifiable 
for such a problem since the number of free parameters far outnumber the number of data. 
The analysis was performed using Data2Dynamics software (Raue et al., 2013, Raue et al., 
2015) and the profile likelihood method to analyses parameter identifiability, as developed by 
Prof Jens TimmerÕs group in Freiburg (Raue et al., 2009, Maiwald et al., 2016). The results 
of this identifiability analysis are illustrated in Figure S2.  
Additionally, local sensitivity analysis indicates that, in line with the complementary MCA 
method (as described in the main manuscript), it is the nodes that are relatively close to the 
transcription factor signal that dominate the subsequent expression following receptor 
activation. These fairly intuitive results suggest that errors arising due to parameter changes 
throughout the system can be mitigated for in order to achieve the same fold-changes seen 
experimentally, provided that (a) other parameters are also changed (in the case of sensitive 
proximal nodes) or (b) because their values are not having a large effect on the downstream 
signal (distal nodes). This emphasises the importance of the use of MCA in the proposed 
methodology as a means of identifying any distal nodes that do affect transcription factor 
signal, as identified in the paper. Of course, to acquire identifiable parameters, far more data 
would be needed (than is available for such a complex network) or typically, a minimal ODE 
model would be constructed that significantly reduces the number of variables and 
parameters that cannot be identified with given data. This minimal approach would 
potentially be useful for answering questions about the dynamics of the H1-histamine 
signalling pathway for a very specific scenario and/or ligand. However, this approach would 
be limited when trying to identify off-target receptor toxicity. 
 Figure S2, related to Figure 2: Identifiability analysis for the H1 Histamine pathway 
Petri net. Briefly, following the identification of a globally optimal parameter set each model 
parameter is perturbed within a prescribed range, one parameter at a time. Starting from the 
optimal value, a single parameter is perturbed, set to be fixed at the new and non-optimal 
value, and the model is then re-fit, i.e. by optimising all other parameters. Then 
corresponding likelihood values are plotted for this new fit. Analysis was conducted using the 
profile likelihood method in Data2Dynamics software, solved in MATLAB 2017b. 
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